Healthcare plan operator Hapvida's planned purchase of certain assets from rival Plamed shouldn't be approved as is, Brazilian antitrust investigators said in an opinion.The case will be referred to the governing Tribunal of the Administrative Council for Economic Defense, or CADE, for a definitive ruling. The opinion from the agency's Superintendence isn't